Open access peer-reviewed chapter

Immunotherapy and Vaccine Development in Viral Hepatitis

By Kazuto Tajiri and Yukihiro Shimizu

Submitted: May 4th 2012Reviewed: December 18th 2012Published: May 29th 2013

DOI: 10.5772/55525

Downloaded: 1912

1. Introduction

More than 300 million people and 170 million people are chronically infected with hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively. To eradicate those viral infections, both prophylactic and therapeutic approaches are required. In HBV infection, there are global programs for prophylactic vaccination. However, some subjects, especially under immunocompromized state, are unable to acquire ant-HBs antibody (Ab) with conventional vaccination, and several attempts to improve the immunogenicity of HB vaccine have been made. On the other hand, development of effective prophylactic HCV vaccine has not been achieved mainly because of high rates of escape mutations within HCV envelope genes. We first focus on the recent development of prophylactic vaccine for HBV and HCV infections.

In the second half of the review, we summarized immunotherapeutic approach for both viral infections. Neither HBV nor HCV is cytopathic, and hepatitis is caused by the host immune response against virus-related peptides expressed on hepatocytes in conjunction with human leukocyte antigens (HLA). In acute self-limiting hepatitis, a broad immune response occurs that is strong enough to eradicate the virus or suppress viral replication [1], indicating that efficient induction of anti-viral immune response could have a potential to control viral infections. However, in chronic hepatitis, there are many mechanisms that hamper the antiviral immune response leading to persistent viral infection.

In chronic HBV infection, strong long-term viral suppression can now be achieved with various nucleoside and nucleotide analogs. However, there are some problems that must be solved in the near future. One of the problems in the treatment of nucleos(t)ide analogs is a low rate of HBe seroconversion even after long-term administration in HBeAg+ patients. Moreover, reactivation rate of HBV replication is high in both HBeAg+ and HBeAg patients after cessation of the treatment, although drug-free viral controls would be better than long-term administration of the drugs in terms of control of medical costs and avoidance of adverse effects of these agents. Therefore, it would be beneficial to achieve long-term viral eradication even after cessation of nucleos(t)ide analogs in combination with efficient immunotherapy.

On the other hand, antiviral oral drugs, such as protease inhibitor or polymerase inhibitor showing potent antiviral ability [2], have been developed for chronic HCV infection. However, not all patients treated with these drugs could achieve sustained virological response and high medical cost for each patient is a global serious problem. Effective immunotherapy combined with these drugs may improve their antiviral effects and control medical costs also in hepatitis C.


2. Problems and recent advances in HBV vaccination

2.1. Non-responder for HBV vaccine (Table 1)

In HBV infection, HBV is transmitted at a high incidence rate by parenteral, percutaneous or sexual contact. Therefore, primary protection is very important and universal vaccination regardless of maternal HBsAg status is recommended. Most of countries have introduced HBV vaccination into their national immunization programs and more than 80% of infants have received HBV vaccine three times. In Taiwan, universal vaccination program of all newborns was introduced in 1986. After twenty years of the program, the rate of chronic HBV infection decreased from 9.8% to 1.2% and the risk of childhood HCC has been decreased by 70% [3, 4].

Host factors
Age > 40 years
Genetics, certain HLA types
Other medical conditions
Renal failure
Conditions requiring immunosuppressive therapy
Unrecognized chronic HBV infection
Subcutaneous administration
Freezing of vaccine

Table 1.

Causes of non-responder to HBV vaccine

Non-responder for HBV vaccination and vaccine escape mutants are important problems to be focused in the future. The general recommendation for non-responders is to repeat a three-dose schedule; 50-75% is expected to respond to the second dose. Non-responders to the second dose should be evaluated for underlying chronic HBV infection. For hemodialysis patients, response may be improved by using double-dose vaccine [5]. Intradermal administration have been tried to improve the effectiveness of vaccination but is technically difficult [6] and long-term efficacy has not been demonstrated. Several trials to improve the effectiveness of HBV vaccination particularly in hemodialysis patients have been investigated (Table 2). Combined use of granulocyte macrophage-colony stimulating factor or levamisole as an adjuvant of HBV vaccination is a promising strategy [7-9]. New chemical adjuvant has also shown an excellent potential [10-12]. On the other hand, Interleukin (IL)-2 is not shown to be effective when used as an adjuvant [13,14]. Recently, a new HBV vaccine including preS lesion, which is known as an essential site for HBV-entry to hepatocyte, has been tried [15,16].

GM-CSFdendritic cell activationMeta-analysis: OR 4.63[7]
Levamisoleinterferon inducerMeta-analysis: OR 2.43[8]
upregulation of defective immune functionMeta-analysis: OR 2.77[9]
Interleukin-2enhanced cellular immunityRCT: no significant effect[13, 14]
HB-AS04upregulation of CD86, increased cytokineRCT: Significant at month 3[10]
(aluminium salt, monophosphoryl lipid (MPL))RCT: Significant[11]
HB-AS02TLR4 agonist, improve antigen presentationRCT: Significant[12]
(MPL, QS21: extract from Quillaja saponaria)
Sci-B-Vac/BioHepBblock HBV-entry to hepatocyte?preS1 antibody 50~60% positive[15, 16]

Table 2.

Human trials to improve the effectiveness of HBV vaccination

GM-CSF;granulocyte macrophage-colony stimulating factor, OR; Odds ratio, RCT; randomized controlled trial, TLR; toll-like receptor

2.2. Escape mutant

Mutations in the small-S protein, commonly glycine to arginine substitution at codon 145 (G145R), have been found in some children born from mothers infected with hepatitis B [17]. Although these mutants have been found in many parts of the world, the prevalence appears to be low and decline in the efficacy of HBV vaccine has not been reported. However, a recent report showed that the mutant HBV was transmitted by sexual contact with a subject who had received universal HBV vaccination [18]. Application of HBV vaccine including preS protein to block infection of HBs mutant could be an effective strategy and should be investigated in the future.

3. Recent advances in HCV vaccine

In the analysis of secondary HCV infection after spontaneously clear primary infection, increased rate of spontaneous viral clearance and broader T-cell responses was found [19]. Actually, an animal study using chimpanzee showed that T-cell vaccine elicits effective immunity against HCV challenge thorough early CD4+ and CD8+ T-cell response [20]. These indicate the induction of protective memory responses against HCV during natural infection and also suggest a possibility for the development of effective prophylactic HCV vaccines.

B-cell response against HCV through the production of neutralizing antibodies has been analyzed for the development of HCV vaccine. In acute HCV infection, the detection of neutralizing antibodies and consequent rapid clearance of HCV had been reported [24]. On the other hand, delayed induction of these neutralizing antibodies has been shown in patients developing chronic HCV infection, [21]. These observations represent that the neutralizing antibodies could not control HCV infection and there are escape mechanisms of HCV from those antibodies. Actually, rapid evolution in the envelope glycoprotein sequences has been demonstrated as the mechanism of HCV evasion [22]. The HCV envelope glycoproteins, E1 and E2, have proven to be the essential region not only for viral attachment but also for viral endocytosis into hepatocytes [23]. Hypervariable region (HVR) is known to be located at the N-terminus of E2 region and is highly immunogenic and the region is necessary for binding to scavenger receptor class B type I (SR-BI), a lipoprotein receptor molecule involved in HCV entry [24,25]. Furthermore, conformational epitope within E2 is known to be conserved among various genotypes of HCV and is necessary for binding to CD81 [26,27]. While, E1 displays a relatively high degree of conservation within subtypes, also suggesting a high degree of intergenotypic cross-neutralization potential [28].

CD4+ and CD8+ T-cell are also important in viral clearance [29-31]. CD4+ T-cells against conserved protein epitopes, such as HCV core, nonstructural (NS)3, NS4 and NS5, have been associated with self-limited infection of HCV. Trials for HCV prophylactic vaccines can be divided into two strategies to induce T-cell response or neutralizing antibodies, but both should be addressed together for an effective prophylaxis strategy. Since acute HCV infection is usually asymptomatic and is not associated with liver failure, prevention from acute to chronic HCV infection is another key goal of vaccine development.

Preclinical evaluation of prophylactic vaccine has been performed in chimpanzee, the only established model for the study of HCV infection in an immunocompetent host. These preclinical trials and the results are summarized in Table 3. Not only humoral responses but also cellular responses were elicited by vaccination, leading to viral clearance after HCV challenge [20,32-37]. Because many chimpanzees spontaneously resolve acute hepatitis C in unvaccinated control groups, definite conclusions for the efficacy of HCV vaccination should be analyzed in human studies. Most vaccine candidates were successful in inducing immune response and reducing viral load. However, protection of infection following challenge with heterologous strains was limited. Although these limited protection shows the difficulty in developing a vaccine against different isolates, these preclinical trials certainly provides information on potential and design of vaccine candidates. As phase I human clinical trial, E1/E2 vaccine adjuvanted with MF59 (an oil-in-water emulsion) was administered to healthy adults, and neutralizing antibodies could be induced without adverse events [38]. Furthermore, these antibodies showed the neutralizing capacities against heterologous virus strains [39]. Further trials should be made for the development of effective HCV vaccines.

E1/E2 protein21 vaccinated/24 controls[32]
2/12 chronic infection after homologous challenge
1/9 chronic infection after heterologous challenge
Strong humoral immune response
15/24 chronic infection in controls
DNA plasmid: E22 vaccinated/1 controls[33]
2/2: viral clearance
High anti-E2 antibodies in one vaccine
E2-specific CD4 T-cell response in the second
DNA plasmid: Core-E1-E2, NS3-56 vaccinated/2 controls[34]
2/6: viral clearance
HCV-specific antibody and T-cell response
Reduced peak viral load in all animals
1 sterilizing immunity: high anti-E2 and strong cellular response
1/2 controls: viral clearance
Adenovirus NS3-NS5B5 vaccinated/5 controls[20]
4/5: viral clearance after 18 months
Peripheral and intrahepatic CD8 T-cell response
3/5 controls: viral clearance
HCV like particle: Core E1-E24 vaccinated/4 controls[35]
4/4: viral clearance after 12 months
HCV specific CD4 and CD8 T-cell response
1/4 controls: viral clearance
DNA plasmid: Core E1-E2 NS34 vaccinated/2 controls[36]
1/4: viral clearance
Reduction of HCV load in serum and liver
Strong HCV CD4 response
Anti-E1 and anti-E2 specific antibodies
Vaccinia virus Core E1-E2-P7 -NS3-NS34 vaccinated/2 controls[37]
1/4: viral clearance after homologous
T-cell response: vigorous IFNγ production and moderate proliferation

Table 3.

Preclinical trials of HCV vaccines in chimpanzees

4. Immnunotherapy for viral hepatitis and vaccine development

To develop efficient immunotherapy, understanding of immune response for eradication or suppression of hepatitis virus during acute hepatitis is important. Moreover, the immunosuppressive mechanisms leading to persistent viral infection need to be analyzed.

4.1. Immune response in acute viral hepatitis

Immunological analysis has been extensively performed in transgenic and chimpanzee models of acute HBV infection. In one model, transgenic mice, in which infectious HBV virions replicate in the liver with expression of all HBV-related antigens, were injected with HBsAg-specific cytotoxic T lymphocytes (CTLs) that had been induced in nontransgenic mice. The transgenic mice produced interferon (IFN)-γ and tumor necrosis factor (TNF)-α, which purged viral RNA and DNA without destroying infected hepatocytes [40,41]. Importantly, this noncytolytic clearance of intracellular HBV is more efficient at controlling HBV replication than the killing of infected hepatocytes. This was confirmed in a chimpanzee infection model [42] and incubation phase of acute hepatitis B in humans [43].

The same is essentially true in acute HCV infection. Multispecific and vigorous CTL responses against HCV antigens are important for successful eradication of the virus. Moreover, a CD4+ T cell response at an early stage of acute infection and persistence of the response are apparent in acute infection [44]. In contrast to acute HBV infection, the majority of patients with acute HCV infection progress to persistent infection, and the mechanisms underlying failure to eradicate the virus have been analyzed. The failure of CD4+ T cell function is a key factor in HCV persistence and CD4+ T cells from persistent infection do not produce Th1 cytokines, such as IFN-γ and IL-2, but produce IL-4 and IL-10, clearly distinct from those seen in patients with recovery [45]. Moreover, an early and strong Th1 response has been shown to play an important role in disease resolution.

The contributions of CD4+ and CD8+ T cells to the control of viral infection were analyzed in a chimpanzee model of acute hepatitis B and C by depleting either T cell population with monoclonal antibodies (Abs). The data showed that both CD4+ and CD8+ T cells are required for virus elimination [46,47].

4.2. Hierarchy of T cell response in viral hepatitis

The antigen-specificity of the T cell response to HBV in acute hepatitis has been analyzed, and it is clear that acute viral hepatitis involves a vigorous CTL response to multiple epitopes in the viral nucleocapsid, envelope, and polymerase proteins, while these are not seen in patients with chronic hepatitis [1]. Although multi-specificity of the CTL response is characteristic in acute hepatitis, there is known to be a hierarchy of epitope-specific CD8+ T cell responses determined by cytokine production after peptide stimulation. In acute hepatitis B, CD8+ T cell response to HBc18-27 (HLA-A2 restricted epitope) is dominant followed by the response to polymerase epitope (455 – 463), whereas envelope epitopes are always subdominant [48]. The hierarchy is clearly distinct from that observed in chronic hepatitis, in which the CD8+ T cell response to envelope epitope (183 – 191) is always dominant. Interestingly, chronic hepatitis patients with lower HBV DNA levels in the serum show greater responses to HBc18-27 than those with high HBV DNA. These findings imply that the T cell response to HBcAg is important for viral control, which is important for designing peptide vaccines for the treatment of chronic HBV infection.

In acute HCV infection, the CTL responses were directed against multiple viral epitopes, in particular within the structural (core) and nonstructural (NS) regions of the virus (NS3, NS4, and NS5), and the CTL frequencies were higher in patients with acute infection [30,49]than in those who develop persistent infection. The hierarchy of HCV epitopes has not been analyzed extensively, but resolution of primary infection in the chimpanzee was shown to be associated with a dominant CD4+ T cells response against epitopes including NS3 (GYKVLVLNPSV) [50].

4.3. Immune response in chronic viral hepatitis

In contrast to acute hepatitis, the T cell response to HBV is weak and is narrowly focused in chronically infected patients [51], suggesting that it may be a cause of persistent infection.

HBV-specific helper and CTLs are barely detectable in peripheral blood of patients with chronic hepatitis B (CHB) [52], possibly due to exhaustion by high viral load or tolerance to HBV.

In contrast to chronic HBV infection, CTL response against various HCV epitopes including core and envelope and NS regions can be detected in chronic HCV infection, especially in liver-infiltrating lymphocytes [53]. Although intrahepatic CTL response was shown associated with low viral load [54], the CTL response is not enough to terminate HCV infection possibly due to the presence of immunosuppressive mechanisms similar to chronic HBV infection.

4.4. Immunosuppressive mechanisms responsible for persistent hepatitis virus infection

4.4.1. Regulatory T cells (Tregs)

In HBV infection, significant accumulation of CD4+CD25+FoxP3+ Treg cells in the liver was found in patients with chronic HBV infection. Moreover, patients with high viral load have a higher proportion of Tregs in the liver [55], suggesting that intrahepatic Tregs suppress antiviral immune responses in the liver in chronic hepatitis B virus infection. In HCV infection, several groups have also shown a higher frequency of CD4+CD25+ regulatory T cells in the blood of chronically HCV-infected patients versus recovered or healthy individuals [56,57] and the presence of CD4+FoxP3+ T cells in the liver of chronically HCV-infected patients [58].

4.4.2. Programmed Death-1 (PD-1)

PD-1 is a surface receptor critical for the regulation of T cell function [59,60]. Binding to PD-1 by its ligands PD-L1 and PD-L2 results in the antigen-specific inhibition of T cell proliferation, cytokine production, and cytolytic function, leading to exhaustion of T cells.

Intrahepatic HBV-specific CD8+ T cells express higher levels of PD-1, and upregulation of intrahepatic PD-1/PD-L1 is associated with liver inflammation and ALT elevation [64]. PD-1/PD-L1 blockade increased CD8+ T cell proliferation and enhanced IFN-γ and IL-2 production by intrahepatic lymphocytes [61].

In chronic HCV infection, circulating and intrahepatic HCV-specific CD8+ T cells were found to express high levels of PD-1 [62], and PD-1 expression level in the liver is higher than that in peripheral blood. Increased expression of PD-1 is associated with CD8+ T cell dysfunction, and functional restoration is achieved by blocking the signal from PD-1 [63]. Interestingly, HCV core protein induces PD-1 and PD-L1 on T cells from healthy donors [64], indicating that immunosuppressive ability of HCV core protein is mediated by the upregulation of inhibitory molecules on T cells. Increased PD-1 expression on HCV-specific CTLs was reported to be significantly associated with poor response to antiviral therapy [65].

4.4.3. IL-10

IL-10 is an important cytokine with anti-inflammatory properties, and is produced by activated monocytes/macrophages and T cell subsets, including Treg and Th1 cells [66]. In chronic HBV infection, HBcAg stimulates the production of IL-10, which negatively regulates HBcAg-specific Th17 cell responses in CHB patients [67].

In HCV infection, HCV proteins have been shown to induce IL-10 from monocytes in patients with chronic HCV infection, leading to suppression of antiviral immune response [68].

4.4.4. T-cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3)

Recently, an inhibitory molecule, Tim-3, has been reported. A high frequency of Tim3-expressing CD4+ and CD8+ T cells are found in chronic HBV infection, and the frequency of Tim-3+ T cells was positively correlated with the severity of liver inflammation, and negatively correlated with plasma IFN-γ levels [69]. Tim-3 was also highly expressed on CD4+ and CD8+ T cells in HCV infection, with the highest levels seen on HCV-specific CTLs. Tim-3 expression is associated with reduced Th1/Tc1 cytokine production, and blocking the Tim-3 – Tim-3 ligand interaction could enhance CD4+ and CD8+ T cell proliferation in response to HCV-specific antigens [70].

4.4.5. Dysfunction of Dendritic Cells (DCs)

In patients with CHB, maturation of DCs from peripheral blood of patients after incubation with cytokines is lower than that of normal subjects with lower expression of HLA-DR and costimulatory molecules in the former population [71], leading to low allostimulatory function of DCs from CHB patients. Interestingly, impaired function of monocyte-derived DCs from patients with CHB could be reversed by inhibiting viral replication with nucleoside analogs such as lamivudine [72]. Type 2 precursor plasmacytoid dendritic cells (pDCs), which are the most important cells in antiviral innate immunity, were also reported to have quantitative and qualitative impairment in patients with chronic HBV infection [73]. Recently, HBV itself was shown to inhibit the functions of pDCs [74].

In chronic hepatitis C, DCs from patients also show impaired immunostimulatory function, which could be induced by HCV [75] or NS4 protein [76]. Monocyte-derived DCs from HCV patients were shown to induce proliferation of CD4+CD25+FoxP3+ regulatory T cells, which limit proliferation of HCV-specific T lymphocytes [77]. DCs in HCV patients thus inhibit T cell responses via a variety of mechanisms.

5. Immunotherapeutic trials for viral hepatitis

Previous basic analyses and human trials in HBV infection are listed in Tables 4 and 5, respectively, and those in HCV infection are summarized in Tables 6 and 7.

Animal modelImmunotherapyResultsRef
Peptide vaccination
HBV transgenic miceA synthesized fusion peptide, consisting HBcAg18-27 and HIV Tat49-57 adjuvanted with CpG ODNDecreased in serum HBV DNA levels and the expression levels of HBsAg and HBcAg in the liver[79]
Protein vaccination
HBV transgenic miceHBsAg vaccineMost of the mice showed reduction of HBV DNA levels and disappearance of HBeAg and HBsAg[83]
Woodchuck hepatitis Virus infectionCombination of vaccine of HBV large surface protein and clevudineRestored T-cell response to Pre-S and S region.[85]
MiceChimeric HBsAg-preS1 proteinPrimed both HBcAg-specific T cells and antibodies to preS1.[86]
Balb/c and HBV transgenic miceChimeric HBsAg-preS1 proteinInduced strong anti-HBc and moderate anti-preS1 immune response, and reduced HBsAg and HBV DNA in HBV-Tg mice.[96]
Balb/c miceChimeric protein with HBcAg and carboxy terminus of the Hsp65Induced moderate anti-HBc immune response and strong HBcAg-specific T cells response.[97]
Balb/c and HBV transgenic miceHBsAg, HBcAg and heat shock protein gp96Decreased serum HBsAg and HBcAg expression in hepatocytes by 45% and 90%, respectively. Decreased serum HBV DNA to below or close to the detection limit.[98]
Balb/c and HBV transgenic miceFusion protein with protein transduction domains from HIV-1-Tat and HBcAgInduced HBcAg-specific CTLs and enhanced production of IFN-γ, IL-2, IL-4 and IL-10. Reduced HBV DNA and HBsAg in the serum and HBsAg expression in liver tissue of HBV transgenic mice.[99]
DNA immunization
WoodchuckDNA vaccine expressing WHsAg was administered by electroporationInduced dose-dependent antibody and T cell responses to WHsAg more efficiently than conventional hypodermic needle injection.[104]
Acute DHBV infectionDNA vaccine expressing DHBc and Pre-S/S and entecavir
Boosted with fowl poxvirus vectors expressing DHBc and Pre-S/S
Cleared DHBV infection at a rate of 100%.[105]
Chronic DHBV
DNA vaccine encoding the HBV large envelope and/or core protein with or without lamivudineReduced viremia and liver DHBV cccDNA in 33% of ducks.
Seroconversion to anti-pre S in 67% of ducks showing cccDNA clearance.
HBV transgenic miceDNA vaccine expressing HBcAg fused to extracellular domain of CTLA-4. Mice were challenged by pAAVNBV1.2Reduced serum HBV DNA and HBcAg in the liver. Clearance of serum HBsAg was also observed.[107]
HBV transgenic miceDNA vaccine expressing HBsAg fused to extracellular domain of CTLA-4.Serum levels of HBsAg and HBV DNA were decreased by induction of anti-HBs Ab and HBsAg-specific CD8+ T cell response.[108]
DC immunization
HBV transgenic miceActivated bone marrow-derived DCsBroke CTL tolerance to HBsAg.[121]
HBV transgenic miceHBV-specific peptide-pulsed DCsReduced in the serum HBsAg and HBV DNA.[122]
HBV transgenic miceAnti-CD40 agonistic monoclonal AbInduced noncytopathic inhibition of HBV replication mediated by antiviral cytokines (IL-12 and TNF-α) produced by activated intrahepatic APCs.[123]
Cytokines and adjuvants
HBV transgenic miceRecombinant IL-12Markedly inhibited HBV replication in the liver.[132]
HBV transgenic miceα-galactosylceramide that can activate NKT cellsInduced complete inhibition of HBV replication.[133]
HBV transgenic miceRecombinant IL-18Inhibited HBV replication noncytopathically, mediated by activation of resident intrahepatic NK cells and NKT cells.[134]
Gene therapy
HBsAg transgenic miceLentivectors expressing HBsAg and IgFc fusion AgInduced seroconversion to anti-HBs.[100]
HBV transgenic miceCationic lipid DNA complexes and HBsAgSuppressed HBV DNA in hepatocytes non-cytopathically.[101]
WoodchuckCationic liposomes and non-coding DNA was administered with WHsAg intramuscularlyInduced rapid and high Ab and T cell response to WHsAg.[102]

Table 4.

Immunotherapeutic approaches for animal models of HBV infection

CpG ODN; CpG oligodeoxynucleotide, WHV; woodchuck hepatitis virus, DHBV; duck hepatitis B virus, cccDNA; covalently closed circular DNA, DC; dendritic cells, CTL; cytotoxic T lymphocytes, APC; Antigen-presenting cells, NKT; natural killer T, Ig; immunoglobulin

Peptide vaccination
A vaccine with HBc18-27 peptide comprised of a T-helper cell epitope and two palmitic acid residuesLow levels of CTL activity were induced but no significant changes in liver biochemistry or viral serology were observed.[80]
Protein vaccination
PreS2/S (GenHevac B) or S (Recombivax).HBe/anti-HBe seroconversion was observed in 13% and HBV DNA negativity was in 16% of the treated patients.[84]
Oral administration of HBV envelope proteins (HBsAg+preS1+preS2)Induced histological improvement in 30%, HBeAg negativity in 26.3% and HBsAg-specific T cell proliferation in 78% of the treated patients.[87]
Combination of lamivudine and HBsAg vaccineInduced sustained negativity of HBV DNA in 1/4 of the patients.[88]
The combination with lamivudune and HBsAg vaccine in HBeAg+ casesNo improvement of HBe seroconversion rate was observed in comparison with lamivudine therapy alone.[89]
Combination of lamivudine and HBsAg vaccineHBV DNA became undetectable in 64% of the patients, and was decreased in the remaining patients.[90]
Intradermal HBsAg vaccine and laimvudine in combination with IL-2Induced significant HBV DNA loss in the serum in two of five of the treated patients.[91]
IFN-α-2b monotherapy (9 months) or IFN-α-2b plus pre-S2/S vaccineInduced greater reduction in HBV DNA in patients with combination HBV therapy than those who received IFN-α-2b monotherapy.[92]
Complexes composed of yeast-derived hepatitis B surface antigen (HBsAg) and antibodiesHBeAg seroconversion rate was 21,6% and was correlated with decrease of HBsAg and HBV DNA.[93]
HB preS/S vaccine (GenHevac B)Caused no effect on HBV DNA and seroconversion of HBeAg to HBeAg in the immunotolerant phase of children with chronic HBV infection.[94,95]
DNA immunization
DNA vaccine encoding HBV envelope proteinInduced an increase in HBV-specific IFN-γ-secreting T cells in nonresponders to conventional therapies, and HBV DNA levels were transiently decreased in 50% of vaccinated patients.[109]
DNA vaccine encoding PreS and S in patients with lamivudine breakthroughInduced IFN-γ-producing T cells specific for preS or S antigen. Two of 10 patients showed seroconversion to anti-HBe.[110]
DNA vaccine encoding HBsAg followed by recombinant modified vaccinia virus Ankara expressing HBsAgFailed in decrease in AST or ALT and did not reduce HBV viremias.[111]
DC immunization
Activated DCs from PBL pulsed with HBsAgInduced anti-HBs and HBsAg-specific cellular immnunity in some patients.[124]
PBL-derived DCs from chronic hepatitis B incubated with a cocktail of cytokines: IL1-β, PGE2, IL-6 and TNF-α, and pulsed with HBsAg or HBcAgInduced autologous T cell proliferation and Ag-specific IFN-γ production.[125]
Peripheral blood-derived DCs, activated with GM-CSF and IL-4 pulsed with HBsAg.Both patients with normal and elevated ALT responded equally to DC vaccine and 53% of the patients showed induction of HBeAg negativity.[126]
Activated DCs from PBL with GM-CSF and IL-4, pulsed with two peptides, HBc18-27 and PreS2 44-53.Undetectable HBV DNA was achieved in 46.3% and 3.13% of HBeAg- and HBeAg+ patients, respectively. ALT normalization was observed in 69% and 30.5% of HBeAg- and HBeAg+ patients, respectively.[127]
GM-CSFSafe and tolerable up to 1.0mg/kg body weight, and induced HBV DNA negativity in 4/8 patients.[135]
Combination therapy with GM-CSF and HBsAg vaccine in HBV carrier childrenSignificantly reduced serum HBV DNA.[136]
High dose of IL-12 (0.5μg/kg)HBV DNA clearance was observed in 25% of the patients.[137]
Combination of IL-12 and lamivudineStimulated T cell response to HBV with IFN-γ production. However, IL-12 was unable to suppress re-elevation of HBV DNA after cessation of lamivudine.[138]
Combination of IL-12 and IL-18Stimulated IFN-γ production by CD4+ T cells isolated from peripheral blood in response to HBcAg, and the effect was greater than those observed with either cytokine alone.[139]
Thymosin-α 1(Talpha1)
Combination of Talpha1 and IFN-αNo significant differences was observed as compared with IFN-α monotherapy with respect to HBeAg seroconversion, changes in histology, normalization of ALT or loss of HBV DNA.[140]
Talpha1 aloneAt 12 months after cessation of therapy, 36.4% of patients treated with 1.6mg of Talpha1 achieved ALT normalization, 15% achieved HBV DNA clearance by transcription-mediated amplification, and 22.8% achieved clearance of HBeAg.[141]
Comparative effect of Talpha1 and IFN-αTalpha1 treatment was more effective in achieving ALT normalization and HBV DNA negativity at the end of the follow-up period than IFN-α.[142]
Combination of Talpha1 and lamivudineNo any additional antiviral effect compared with lamivudine monotherapy as assessed by HBe seroconversion and the emergence of viral breakthrough.[143]
Combination therapy with lamivudine and Talpha1Induced significantly higher rates of ALT normalization, virological response, and HBeAg seroconversion than lamivudine monotherapy.[145]

Table 5.

Immunotherapeutic trials for chronic HBV infection in humans

CTL; cytotoxic T lymphocytes, GM-CSF; granulocyte macrophage-colony stimulating factor

Animal modelVaccineResultsRef.
Protein vaccination
ChimpanzeeRecombinant HCV-like particles containing core, E1 and E2 proteinsIncreased in peripheral and intrahepatic T cell proliferative responses against the HCV proteins.[35]
DNA immunization
HCV transgenic mouse modelThe combination of DNA vaccination encoding HCV core and mouse IL-2Broke tolerance against HCV and activates previously tolerant T cells.[112]
Mice expressing HCV antigens in the liverHCV NS3/NS4 DNA vaccineInduced HCV-specific CD8+ T cells expressing IFN-γ and CCR5 and cleared HCV NS3 expressing hepatocytes.[113]
MiceMurine DCs with CFm40L transfected with adenovirus encoding HCV NS3Induced CD4+ and CD8+ T cell response against HCV NS3.[114]
MiceDCs transfected with adenovirus encoding HCV NS3Induced multiepitopic CD4+ (Th1) and D8+ T cell response and down-regulated the expression of HCV RNA in the liver.[115]
Balb/c and HLA-A2.1 trangenic miceDCs transfected with adenovirus encoding HCV NS3Induced NS3-specific cell mediated and humoral immune response.[116]
Chimpanzee with HCV-challengeRecombinant adenoviral vectors encoding the HCV NS3-5B (genotype 1b) and with NS3-5B–encoding plasmid DNA in a combined modality regimenHCV NS3-NS5, HCV-specific T cells appeared earlier, maintained better functionality, and persisted at higher frequencies. The T cells controlled HCV-challenge.[117]
DC immunization
HCV transgenic mouse modelDCs treated with peptide inhibitors of IL-10Induced strong anti-HCV T cell responses[128]
Gene therapy
C57BL/6 and BALB/c miceAdenovirus-besed HCV vaccine by fusing HCV NS3 to MHC class II chaperone protein invariant chainInduced CD8+ T cells expressing IFN-γ, TNF-α, IL-2, CD27 and CD127. The CD8+ T cells protected mice from infection with recombinant vaccinia virus expressing HCV NS3 of heterologous 1b strains[129]

Table 6.

Immunotherapeutic approaches for animal models of HCV infection

Peptide vaccination
A vaccine, IC41, containing 7 relevant HCV T cell epitopes and the Th1 adjuvant poly-L-arginineInduced HCV-specific Th1/Tc1 responses in a subset of HCV patients not responding to or relapsing from standard therapy. However, only a minimal decrease in HCV viremia was induced by the vaccination.[81]
Vaccination with a peptide derived from HCV core proteinInduced both cellular and humoral responses in nearly all HCV patients with different HLA class I-A alleles, and reduced serum ALT and AFP levels in 29% and 50% of patients, respectively.[82]
DNA vaccination
A new vaccine, CIGB0230, consisting of a mixture of plasmid expressing HCV structural antigens and HCV recombinant core proteinInduced specific T cell proliferation and IFN-γ production in 73%. More than 40% of the vaccines showed improvement of liver histology, despite persistent detection of HCV RNA.[99]
DC vaccination
Human DCs from HCV-infected patienst with CFh40L transfected with adenovirus encoding HCV NS3Induced CD4+ and CD8+ T cell response against HCV NS3 in HCV-infected patients[114]
Monocyte-derived DCs loaded with lipopeptides consisting of HCV-specific HLA-A2.1-restricted CTL epitopesInduced HCV-specific CD8+ T cell responses with IFN-γ production in PBL in HCV patients in whom conventional IFN-based therapy has failed. However, ALT levels were not elevated and viral load was not decreased.[118]
Human DCs infected with adenoviral vectors harboring HCV core and NS3Induced CD4+ and CD8+ T cell response against HCV core and NS3 in healthy subjects[130]
Human DCs infected with adenoviral vectors harboring HCV NS genesDCs transfected with adenovirus NS3/NS4 efficiently induced HCV-specific immunity in healthy subjects[131]
Talpha1Patients with chronic HCV infection who had been nonresponders to prior IFN-α and ribavirin were treated with Talpha1, PEG-IFN α-2a, and ribavirin for 48 weeks. Twenty-four percent of the treated patients with genotype 1 achieved a sustained virological response.[144]
Blockade of inhibitory signals
Blocking PD-1, CTLA-4 and IL-10 combined with therapeutic vaccinationSynergistically enhanced functional CD8+ T cell response and improve viral control in chronically infected mice. Moreover, addition of stimulatory signals, such as IL-2, could further increase the efficacy of the therapy in chronic viral infection[146]
Combined blockade of CTLA-4 and PD-1Combined blockade of CTLA-4 and PD-1, but not blocking of either molecule, can reverse CD8+ T cell exhaustion in HCV infected patients[147]
Blocking Tim-3/Tim-3 ligandBlocking Tim-3/Tim-3 ligand induced intrahepatic T cell proliferation and IFN-γ production in response to HCV antigens in HCV-infected patients[70]
Blockade of Tim-3 on human HCV-specific CTLsBlockade of Tim-3 on human HCV-specific CTLs fron HCV-infected patients increased cytotoxicity against an HCVAg-expressing hepatocyte cell line that expresses HCV epitopes[149]
Gene transfection
Human T cells transduced with HCV TCR specific for HCV NS3 1071-1081 (HLA A2-restricted epitope)T cells recognized the peptide and produced IFN-γ, IL-2 and TNF-α in healthy subjects[119]
Two adenoviral vectors expressing NS3, 4 and 5 proteins from HCV genotype 1BInduced HCV-specific CD4+ and CD8+ T cells subsets secreting IL-2, IFN-γ, and TNF-α and could be sustained for at least a year after boosting.[120]
Recombinant virus
Recombinant poxvirus vaccine, TG4040, that expresses the hepatitis C virus (HCV) proteins NS3, NS4, and NS5B.It was safe and well-tolerated. It induced HCV-specific immune response and a transient decrease in HCV viremia (>1log) in 33% of HCV-infected patients.[103]

Table 7.

Immunotherapeutic approach for chronic HCV infection in humans

CTLA-4; cytotoxic T lymphocyte antigen-4, PD-1; programmed death-1, Tim-3; T cell Immunoglobulin and Mucin domain containing-3

5.1. Suppression of viral replication

High viral load has been shown to suppress CD4+ and CD8+ T cells in addition to induction of Tregs, which could be reversed by antiviral therapy [78]. Therefore, immunotherapy followed by restoration of virus-specific T cell response with antiviral therapy could be more efficient.

5.2. Induction of immune response to hepatitis virus

5.2.1. Peptide immunization

A fusion peptide consisting of HBc18-27 and HIV Tat49-57 was synthesized, and the vaccination induced significant anti-viral effect in HBV transgenic mice [79]. However, in humans, peptide vaccine containing highly immunogenic HBc18-27 administered to CHB patients, showed disappointing results [80], because there was no induction of a significant antiviral T cell response.

In HCV infection, a vaccine, IC41, containing 7 HCV T cell epitopes and the Th1 adjuvant induced HCV-specific Th1/Tc1 responses in chronic HCV patients, but anti-viral effects were minimal [81]. Another HCV vaccine with a peptide derived from HCV core protein induced both cellular and humoral responses in HCV patients and reduced serum alanine aminotransferase (ALT) and alpha-fetoprotein (AFP) in some patients [82].

5.2.2. Protein immunization

In a model of HBV in transgenic mice, HBsAg vaccine in complete Freund’s adjuvant once a month for 12 months induced reduction in HBV DNA, and the disappearance of HBeAg and HBsAg in most mice treated [83]. Interestingly, some mice developed anti-HBs in the sera. However, several human trials with HBsAg vaccine showed limited efficacy if used as monotherapy.

Recently, HB vaccine containing not only S protein but also preS has been used with increased immunogenicity [84-88], or has been combined with lamivudine [89,90], IL-2 [91] or IFN-α [92] leading to potential improvement of clinical efficacy [93-95]. Moreover, vaccines containing HBcAg have been developed, and some showed significant anti-viral effect in HBV transgenic mice [96-99]. Because T cell response to HBcAg is important for viral control, these vaccines may have a promising immunothepapeutic potential also in humans. Recently, some trials to enhance the immunogenicity of HBV vaccine in combination with adjuvant or by using viral vectors have been made [100-102].

In HCV infection, a recombinant poxvirus vaccine expressing HCV NS3, NS4 and NS5B, TG4040, has been recently developed [103] and administered to HCV patients. The vaccine was safe and induced HCV-specific cellular immune response and reduction in viremia. These data are encouraging, and further large scale clinical trials need to be done.

5.2.3. DNA immunization

Injection of plasmid DNA has been shown to strongly elicit both cellular and humoral immune responses. DNA vaccine is now shown to be safe and well-tolerated, and has been tried in humans with some encouraging anti-viral effects both in mice and humans [104].

In a model of duck hepatitis B virus infection, DNA vaccine encoding HBV large envelope and/or core protein was shown to induce reduction in not only viremia [105] but also cccDNA in the liver in one third of ducks receiving DNA monotherapy or combination treatment along with lamivudine [106]. This finding is encouraging because clearance of cccDNA from the liver is the goal of treatment for HBV infection, but is difficult to achieve using IFN-α or nucleoside analogs. More recently, DNA vaccine expressing HBcAg or HBsAg in combination with extracellular domain of CTLA-4 have been developed and showed significant anti-viral effects in HBV transgenic mice [107,108]. In humans, safety and therapeutic potential of DNA vaccines have been already explored in chronic HBV carriers [109-111].

In HCV infection, DNA vaccine encoding HCV core and IL-2 breaks tolerance and activates previously tolerant T cells in HCV transgenic mice [112]. NS3-specific T cells were induced by DNA immunization in mice models [113-116]. In chimpanzee models, NS3-specific T cells were also induced and HCV-challenge could be controlled [117]. In HCV patients, a new DNA vaccine, CIGB0230, consisting of a mixture of plasmid expressing HCV structural antigens induced HCV-specific T cell response and improved liver histology [118]. Furthermore, trials to elicit HCV-specific T cells response by transduction of HCV-specific T cell receptor or by new type vaccines have been made [119,120].

5.2.4. DC immunization

DCs are specialized antigen-presenting cells that can induce strong immune responses in T and B cell. We have previously shown that activated bone marrow-derived DCs can break CTL tolerance to HBsAg in HBV transgenic mice [121]. Thereafter, several immunotherapies with activated DCs have been applied in both animals and humans. In a recent study performed in HBV transgenic mice, peptide-pulsed DCs were shown to significantly reduce the concentrations of serum HBsAg and HBV DNA [122], indicating therapeutic potential in chronic HBV infection. Moreover, when intrahepatic antigen-presenting cells, including DCs, were activated by injection of anti-CD40 agonistic Ab, HBV replication was inhibited by a noncytopathic mechanism possibly through production of antiviral cytokines such as TNF-α and IL-12 [123]. Although no CTL response against HBV antigens was reported in this study, the in vivo activation of DCs could be an alternative way for inducing antiviral immune responses including possible activation of CTLs against HBV. In humans, injection of activated DCs loaded with HBV peptide or protein achieved the induction of HBV-specific immunity [124,125] and a reduction in HBV DNA level in some patients [126,127]. HBeAg negativity was achieved in more than half of the treated patients in one study [126].

In HCV infection, DCs treated with peptide inhibitors of IL-10 were shown to induce strong anti-HCV T cells response in HCV transgenic mice [128], suggesting a strategy to augment the immunogenic function of DCs. Recently, murine DCs infected with adenovirus encoding HCV NS3 were used as vaccines, and showed induction of NS3-specific T cell response and antiviral effect [129]. In humans, DCs infected with adenovirus vectors harboring HCV core or NS genes, especially NS3, were administered in healthy subjects [130,131] and HCV patients [114,118], and those DCs induced CD4+ and CD8+ T cell response in both populations. Although preparation of activated and mature DCs incurs financial costs and requires experienced researchers, immunotherapy with DCs is a promising method.

5.2.5. Cytokines and Thymosin-α1 (Talpha1)

Cytokines, such as IL-12 [132] and IL-18 [133], and the activation of NKT cells [134] were shown to inhibit HBV replication noncytopathically in HBV transgenic mice. In humans, GM-CSF [135,136] and IL-12 [137-139] have been used for treatment with some antiviral effects. They have been used as monotherapy or in combination with HBsAg vaccine or lamivudine.

Talpha1, a synthetic 28-amino acid peptide, is able to enhance the Thl immune response and also exerts a direct antiviral mechanism of action. It has been used for the treatment of chronic HBV [140-143] and HCV [144] infection in humans, and showed antiviral effect with some efficacy. Although antiviral effect by the addition of Talpha1 to lamivudine or IFN-α therapy was controversial, a meta analysis demonstrated that the combination therapy with lamivudine and Talpha1 showed significantly higher rates of ALT normalization, virological response, and HBeAg seroconversion as compared with lamivudine monotherapy [145]. It is of note that HBeAg seroconversion rate was 45% in the combination group, which was significantly higher than that with lamivudine monotherapy (15%).

Figure 1.

5.2.6. Blockade of inhibitory signals

There have been several basic attempts to improve the efficacy of immunotherapy. Among these reports, augmentation or restoration of T cell response by blocking the inhibitory signals have been extensively analyzed in vitro. It has been demonstrated that exhausted T cells express not only PD-1, but also CTLA-4 [146,147], CD244 [148] or Tim-3 [70,149], and blocking of these molecules in combination could be better than blocking any single molecule to achieve full activation of the exhausted T cells.


6. Conclusion

There have been several advances in immunotherapy and vaccine development both for prophylactic and therapeutic purposes in HBV and HCV infections and some of the data are promising. For therapeutic purposes, viral suppression, stimulation of antiviral immune response with vaccines with peptides, proteins, plasmid or DC, blockade of immunoinhibitory signals must be combined to achieve desirable antiviral effects (Fig.1). Further studies are required to explore the best protocols and their most efficient combinations to become a promising and practical treatment.

© 2013 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Kazuto Tajiri and Yukihiro Shimizu (May 29th 2013). Immunotherapy and Vaccine Development in Viral Hepatitis, Practical Management of Chronic Viral Hepatitis, Gaetano Serviddio, IntechOpen, DOI: 10.5772/55525. Available from:

chapter statistics

1912total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Clinical Application of Non-Invasive Markers of Liver Fibrosis

By Hadi Parsian, Maryam Alizadeh and Yousef Yahyapour

Related Book

First chapter

The Phylogeny and Classification of Anopheles

By Ralph E. Harbach

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us